Wall Street analysts changed ratings for top names. Visit our analyst ratings page for details. SGP

Wall Street flipped the script Friday with a wave of surprise upgrades and downgrades hitting names

Raymond James analyst Christopher Raymond initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with

Enrollment remains on track in the registrational Phase 3 trials of the Bimatoprost Drug Pad-IOL Sys

Spyglass Pharma, Inc. (NASDAQ: SGP - Get Free Report)'s stock price gapped up prior to trading on Fr

Affinity Asset Advisors LLC purchased a new position in shares of Spyglass Pharma, Inc. (NASDAQ: SGP

ALISO VIEJO, Calif., June 15, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass

ALISO VIEJO, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass

ALISO VIEJO, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass

SpyGlass Pharma, Inc. (NASDAQ:SGP) (SpyGlass Pharma), a late-stage biopharmaceutical company, today

ALISO VIEJO, Calif., May 18, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlass

SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(0.69) per share which missed the analyst

ALISO VIEJO, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass

Spyglass Pharma (NASDAQ: SGP - Get Free Report) and Longevity Health (NASDAQ: XAGE - Get Free Report

SpyGlass Pharma (NASDAQ:SGP) reported quarterly losses of $(5.72) per share. This is a 24.89 percent

ALISO VIEJO, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGla

Nanovibronix (NASDAQ: FEED - Get Free Report) and Spyglass Pharma (NASDAQ: SGP - Get Free Report) ar

Spyglass Pharma (NASDAQ: SGP - Get Free Report) and Longevity Health (NASDAQ: XAGE - Get Free Report

HC Wainwright & Co. analyst Yi Chen initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a

12-month results from the Phase 1/2 trial evaluating its lead product candidate, the Bimatoprost Dru

ALISO VIEJO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (SpyGlas

ALISO VIEJO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGla

Middle East tensions are wreaking havoc, with traditional safe havens not providing much protection.

Wall Street analysts changed ratings on top companies. See full list at benzinga.com/analyst-stock-r

Citigroup analyst Yigal Nochomovitz initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy

Leerink Partners analyst Marc Goodman initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a O

Pre-Market Stock Futures: Futures are down big as oil shoots higher on Tuesday. After a big early mo

Jefferies analyst Dennis Ding initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy ratin

Top Wall Street analysts changed outlook on top names. Check out analyst ratings page for all change

Stifel analyst Tom Stephan initiates coverage on SpyGlass Pharma (NASDAQ:SGP) with a Buy rating a

Four stocks seeing the most notable insider purchases in the past week or so were biotechs SpyGlass

Assistant Secretary for International Finance Charles Collyns Written Testimony before the House Com

UPDATE: ISI Group Initiates Coverage on NetApp at Buy, $48 PT

Benzinga's Political Roundup

Time Warner Director Buys $1 Million Worth Of Shares (TWX, SGP)

The World's Largest M&A Deals in 2009 (PFE, WLA, GM, SGP, MRK)

Priceline.com Added To The S&P 500, Replacing Schering-Plough

European Commission Approves Schering-Plough (SGP) and Centocor's Simponi Drug

US Court Rejects the Attempt by Schering-Plough's (SGP) to Repatriate $690M without Taxes

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 14, 2009) - NOT FOR DISTRIBUTION TO UNITED STATES